Added allopurinol,
does it really help with Prevention of major cardiovascular events in gout-free ischemic heart disease?
research showsGrade D, 34 points. In 5,721 mITT participants, the composite occurred in 314/2,853 (11.0%) versus 325/2,868 (11.3%), absolute difference -0.3 points, HR 1.04 (95% CI 0.89 to 1.21). The interval still permits up to 11% relative benefit.
ads claimUrate lowering does not establish cardiovascular prevention.
Useful facts when choosing a product
- Allopurinol is a prescription urate-lowering gout medicine.
- Rare severe hypersensitivity and skin reactions occur.
What the research actually shows
Four-gate review: ① Unmasked subjective endpoint ② listed item ③ open-label treatment but blinded adjudication of objective events ④ criterion not met. ① At least 15% attrition ② listed item ③ mITT included 5,721 and survival censoring is not attrition ④ no qualifying fixed-time missingness established. No placebo was not invented as a defect.
Why this is classified as D (34)
One large publicly funded null hard-outcome trial with a residual CI tail gives D, 34.
Counterpoint. Gout treatment is separate.
Rejudgment record. Source checked — Large PROBE hard-outcome RCT with null findings
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of major cardiovascular events | D | HR was 1.04. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Multicenter randomized open-label blinded-endpoint trial | 5,721 | UK NIHR HTA | Nonfatal MI, nonfatal stroke, or cardiovascular death | 314/2,853 (11.0%) vs 325/2,868 (11.3%); HR 1.04 (95% CI 0.89 to 1.21) | Large hard-outcome RCT |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] No Benefit of Adding Allopurinol for Preventing Major Cardiovascular Events in Ischaemic Heart Disease — Evidence Grade D·34. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/allopurinol-ischaemic-heart-disease-cardiovascular-events/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.